Is myelo-ablative pretransplant conditioning really myelo-ablative: Implications for radiation and nuclear accidents?

Competing interests

RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd. HML is a consultant to Partner Therapeutics, Lexington, MA.

Comments (0)

No login
gif